Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free AMLX Stock Alerts

Amylyx Pharmaceuticals (AMLX) Financials

Amylyx Pharmaceuticals logo
$16.44 -0.02 (-0.10%)
Closing price 03:59 PM Eastern
Extended Trading
$16.43 -0.01 (-0.05%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Amylyx Pharmaceuticals

Annual Income Statements for Amylyx Pharmaceuticals

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -88 -198 49 -302 -145
Consolidated Net Income / (Loss)		 -88 -198 49 -302 -145
Net Income / (Loss) Continuing Operations		 -88 -198 49 -302 -145
Total Pre-Tax Income 		-88 -198 54 -302 -145
Total Operating Income		 -83 -201 39 -315 -153
Total Gross Profit		 0.29 19 355 81 0.00
Total Revenue		 0.29 22 381 87 0.00
Operating Revenue		 0.29 22 381 87 0.00
Total Cost of Revenue		 0.00 2.99 25 5.95 0.00
Operating Cost of Revenue		 0.00 2.99 25 5.95 0.00
Total Operating Expenses		 83 221 317 396 153
Selling, General & Admin Expense		 39 127 188 114 63
Research & Development Expense		 44 93 128 140 90
Other Operating Expenses / (Income)		 - - 0.00 119 0.00
Restructuring Charge		 - - 0.00 23 0.00
Total Other Income / (Expense), net		 -5.24 3.74 15 13 8.60
Interest & Investment Income		 0.04 4.29 16 14 9.30
Other Income / (Expense), net		 -5.28 -0.55 -0.66 -1.21 -0.70
Income Tax Expense		 0.00 0.77 5.03 -0.39 0.05
Basic Earnings per Share		 ($13.35) ($3.39) $0.73 ($4.43) ($1.53)
Weighted Average Basic Shares Outstanding		 6.59M 58.50M 67.23M 68.14M 94.57M
Diluted Earnings per Share		 ($13.35) ($3.39) $0.70 ($4.43) ($1.53)
Weighted Average Diluted Shares Outstanding		 6.59M 58.50M 69.99M 68.14M 94.57M
Weighted Average Basic & Diluted Shares Outstanding		 - 66.72M 67.78M 88.60M 110.54M

Quarterly Income Statements for Amylyx Pharmaceuticals

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 22 21 4.73 -119 -73 -73 -38 -36 -41 -34 -33
Consolidated Net Income / (Loss)		 22 21 4.73 -119 -73 -73 -38 -36 -41 -34 -33
Net Income / (Loss) Continuing Operations		 22 21 4.73 -119 -73 -73 -38 -36 -41 -34 -33
Total Pre-Tax Income 		24 22 6.48 -119 -73 -73 -38 -36 -41 -34 -33
Total Operating Income		 20 19 1.93 -122 -76 -76 -41 -38 -43 -36 -37
Total Operating Expenses		 72 79 97 205 75 76 40 38 43 36 37
Selling, General & Admin Expense		 43 49 52 58 22 18 17 16 16 16 15
Research & Development Expense		 29 30 45 37 23 57 23 22 27 20 21
Total Other Income / (Expense), net		 3.81 3.69 4.54 3.58 3.59 2.96 2.47 1.90 1.41 1.64 3.65
Interest & Investment Income		 3.89 4.18 4.37 4.33 4.07 3.10 2.32 2.23 1.96 1.82 3.29
Other Income / (Expense), net		 -0.08 -0.49 0.17 -0.75 -0.48 -0.14 0.16 -0.34 -0.55 -0.18 0.36
Income Tax Expense		 1.93 1.52 1.75 0.24 0.00 0.00 -0.64 0.00 0.00 0.00 0.05
Basic Earnings per Share		 $0.33 $0.31 $0.07 ($1.75) ($1.07) ($1.07) ($0.54) ($0.42) ($0.46) ($0.37) ($0.28)
Weighted Average Basic Shares Outstanding		 67.23M 67.41M 67.23M 67.85M 68.02M 68.09M 68.14M 85.70M 89.14M 93.33M 94.57M
Diluted Earnings per Share		 $0.31 $0.30 $0.07 ($1.75) ($1.07) ($1.07) ($0.54) ($0.42) ($0.46) ($0.37) ($0.28)
Weighted Average Diluted Shares Outstanding		 70.13M 69.75M 69.99M 67.85M 68.02M 68.09M 68.14M 85.70M 89.14M 93.33M 94.57M
Weighted Average Basic & Diluted Shares Outstanding		 67.38M 67.52M 67.78M 68.01M 68.08M 68.55M 88.60M 89.14M 89.17M 109.82M 110.54M

Annual Cash Flow Statements for Amylyx Pharmaceuticals

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 37 13 108 -92 149
Net Cash From Operating Activities		 -75 -180 12 -168 -123
Net Cash From Continuing Operating Activities		 -75 -180 12 -168 -123
Net Income / (Loss) Continuing Operations		 -88 -198 49 -302 -145
Consolidated Net Income / (Loss)		 -88 -198 49 -302 -145
Depreciation Expense		 0.05 0.49 1.09 0.90 0.53
Amortization Expense		 0.12 -2.06 -9.94 -9.86 -5.53
Non-Cash Adjustments To Reconcile Net Income		 8.37 23 37 191 29
Changes in Operating Assets and Liabilities, net		 4.60 -3.28 -66 -48 -2.81
Net Cash From Investing Activities		 -46 -239 92 76 14
Net Cash From Continuing Investing Activities		 -46 -239 92 76 14
Purchase of Property, Plant & Equipment		 -0.35 -2.53 -1.24 -0.16 -0.14
Acquisitions		 - - 0.00 -36 0.00
Purchase of Investments		 -49 -416 -301 -232 -232
Sale and/or Maturity of Investments		 3.00 179 394 344 246
Net Cash From Financing Activities		 159 432 3.54 0.35 257
Net Cash From Continuing Financing Activities		 159 432 3.54 0.35 257
Issuance of Debt		 12 0.00 - 0.00 256
Other Financing Activities, net		 12 231 3.54 0.35 0.72
Effect of Exchange Rate Changes		 0.01 -0.07 0.16 -0.44 1.07

Quarterly Cash Flow Statements for Amylyx Pharmaceuticals

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 133 -113 35 0.35 -96 -2.44 5.56 -18 -1.68 167 1.48
Net Cash From Operating Activities		 8.61 -5.17 14 -0.49 -67 -42 -59 -40 -25 -30 -28
Net Cash From Continuing Operating Activities		 8.61 -5.17 14 -0.49 -67 -42 -59 -40 -25 -30 -28
Net Income / (Loss) Continuing Operations		 22 21 4.73 -119 -73 -73 -38 -36 -41 -34 -33
Consolidated Net Income / (Loss)		 22 21 4.73 -119 -73 -73 -38 -36 -41 -34 -33
Depreciation Expense		 0.28 0.30 0.30 0.32 0.21 0.22 0.16 0.16 0.14 0.12 0.11
Amortization Expense		 -1.98 -2.48 -2.57 -2.58 -3.18 -2.31 -1.79 -1.70 -1.52 -1.24 -1.06
Non-Cash Adjustments To Reconcile Net Income		 10 11 8.20 121 18 44 5.42 7.35 8.20 7.41 6.25
Changes in Operating Assets and Liabilities, net		 -22 -35 2.89 -0.31 -9.18 -11 -25 -9.72 9.38 -2.27 -0.20
Net Cash From Investing Activities		 123 -108 21 0.82 -29 39 65 -44 23 5.24 29
Net Cash From Continuing Investing Activities		 123 -108 21 0.82 -29 39 65 -44 23 5.24 29
Purchase of Property, Plant & Equipment		 -0.28 -0.36 -0.36 -0.07 -0.09 0.02 -0.02 -0.01 -0.02 -0.02 -0.09
Purchase of Investments		 - -164 -127 -73 -159 - - -104 -39 -59 -30
Sale and/or Maturity of Investments		 124 57 148 74 130 75 65 60 62 64 60
Net Cash From Financing Activities		 1.38 0.89 0.23 0.13 0.03 0.08 0.11 66 -0.03 192 -0.21
Net Cash From Continuing Financing Activities		 1.38 0.89 0.23 0.13 0.03 0.08 0.11 66 -0.03 192 -0.21
Issuance of Debt		 - - - 0.00 - - - 66 - 191 -0.38
Other Financing Activities, net		 1.38 0.89 0.23 0.13 0.03 0.08 0.11 0.09 -0.03 0.50 0.17
Effect of Exchange Rate Changes		 -0.02 -0.13 0.24 -0.11 -0.04 0.24 -0.53 0.20 0.61 0.15 0.12

Annual Balance Sheets for Amylyx Pharmaceuticals

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 106 391 517 194 333
Total Current Assets		 105 382 465 189 324
Cash & Equivalents		 50 63 170 77 227
Short-Term Investments		 46 284 201 99 90
Accounts Receivable		 0.00 15 40 0.45 0.09
Prepaid Expenses		 5.39 10 15 12 6.60
Plant, Property, & Equipment, net		 0.47 2.61 2.69 0.96 0.31
Total Noncurrent Assets		 0.19 6.71 50 3.22 6.17
Other Noncurrent Operating Assets		 0.19 6.71 50 3.22 6.17
Total Liabilities & Shareholders' Equity		 106 391 517 194 333
Total Liabilities		 17 51 84 29 27
Total Current Liabilities		 17 47 82 28 23
Accounts Payable		 4.37 6.26 22 2.94 3.52
Accrued Expenses		 13 38 58 24 18
Other Current Liabilities		 0.00 2.04 2.26 1.52 1.26
Total Noncurrent Liabilities		 0.04 4.24 1.98 0.46 4.70
Noncurrent Deferred Revenue		 0.04 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.00 4.24 1.98 0.46 4.70
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 239 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -151 341 433 165 305
Total Preferred & Common Equity		 -151 341 433 165 305
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -151 341 433 165 305
Common Stock		 4.67 695 738 772 1,056
Retained Earnings		 -156 -354 -305 -607 -751
Accumulated Other Comprehensive Income / (Loss)		 0.01 -0.09 0.20 -0.09 0.40

Quarterly Balance Sheets for Amylyx Pharmaceuticals

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 181 408 454 467 417 332 251 220 195 363
Total Current Assets		 172 389 427 434 411 327 245 216 187 353
Cash & Equivalents		 108 115 248 135 171 75 72 60 58 225
Short-Term Investments		 55 231 110 220 203 235 163 144 123 119
Accounts Receivable		 0.14 18 33 29 20 4.09 1.73 0.30 0.10 0.13
Prepaid Expenses		 8.34 13 12 17 17 13 9.14 12 5.96 9.26
Plant, Property, & Equipment, net		 2.12 2.56 2.64 2.76 2.46 1.47 1.25 0.82 0.45 0.40
Total Noncurrent Assets		 7.13 16 24 30 4.46 3.97 4.20 2.72 7.26 8.96
Other Noncurrent Operating Assets		 7.13 16 24 30 4.46 3.97 4.20 2.72 7.26 8.96
Total Liabilities & Shareholders' Equity		 181 408 454 467 417 332 251 220 195 363
Total Liabilities		 37 55 67 48 93 71 55 18 27 31
Total Current Liabilities		 33 52 64 46 92 70 54 18 21 26
Accounts Payable		 7.05 11 25 6.37 21 4.96 1.49 4.81 3.29 5.34
Accrued Expenses		 24 39 37 37 68 63 50 12 17 19
Other Current Liabilities		 1.99 2.09 2.15 2.20 2.31 2.37 1.97 1.06 0.67 0.98
Total Noncurrent Liabilities		 4.77 3.69 3.14 2.57 1.38 0.77 0.60 0.33 5.30 4.95
Other Noncurrent Operating Liabilities		 4.77 3.69 3.14 2.57 1.38 0.77 0.60 0.33 5.30 4.95
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 144 353 386 418 324 261 196 201 168 332
Total Preferred & Common Equity		 144 353 386 418 324 261 196 201 168 332
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 144 353 386 418 324 261 196 201 168 332
Common Stock		 456 705 717 728 748 758 765 844 851 1,050
Retained Earnings		 -312 -353 -331 -310 -424 -496 -569 -643 -684 -718
Accumulated Other Comprehensive Income / (Loss)		 -0.73 0.03 -0.07 -0.15 -0.08 -0.10 0.64 0.00 0.55 0.82

Annual Metrics And Ratios for Amylyx Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 - - - 109,819,569.00
DEI Adjusted Shares Outstanding		 0.00 - - - 109,819,569.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 - - - -1.32
Growth Metrics		 - - - - -
Profitability Metrics		 - - - - -
Net Operating Profit after Tax (NOPAT)		 -58 -141 35 -220 -107
Return On Investment Capital (ROIC_SIMPLE)		 - - 8.12% -133.71% -35.15%
Earnings before Interest and Taxes (EBIT)		 -88 -202 38 -316 -154
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -88 -203 29 -325 -159
Valuation Ratios		 - - - - -
Leverage & Solvency		 - - - - -
Liquidity Ratios		 - - - - -
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -143 -33 -147 -105
Efficiency Ratios		 - - - - -
Capital & Investment Metrics		 - - - - -
Invested Capital		 -7.94 -6.34 62 -12 -14
Increase / (Decrease) in Invested Capital		 0.00 1.60 68 -74 -2.46
Book Value per Share		 ($22.95) $5.14 $6.42 $2.40 $2.78
Tangible Book Value per Share		 ($22.95) $5.14 $6.42 $2.40 $2.78
Total Capital		 88 341 433 165 305
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -96 -347 -371 -177 -317
Capital Expenditures (CapEx)		 0.35 2.53 1.24 0.16 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.56 -11 11 -15 -16
Debt-free Net Working Capital (DFNWC)		 88 336 383 161 301
Net Working Capital (NWC)		 88 336 383 161 301
Net Nonoperating Expense (NNE)		 30 57 -14 81 37
Net Nonoperating Obligations (NNO)		 -96 -347 -371 -177 -319
Total Depreciation and Amortization (D&A)		 0.17 -1.57 -8.85 -8.95 -5.00
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.39) $0.73 ($4.43) ($1.53)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 58.50M 67.23M 68.14M 94.57M
Adjusted Diluted Earnings per Share		 $0.00 ($3.39) $0.70 ($4.43) ($1.53)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 58.50M 69.99M 68.14M 94.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 66.72M 67.78M 88.60M 110.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -58 -141 35 -204 -107
Debt Service Ratios		 - - - - -
Payout Ratios		 - - - - -

Quarterly Metrics And Ratios for Amylyx Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - 88,602,468.00 89,141,087.00 89,167,432.00 109,819,569.00
DEI Adjusted Shares Outstanding		 - - - - - - - 88,602,468.00 89,141,087.00 89,167,432.00 109,819,569.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - -0.41 -0.46 -0.39 -0.30
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 19 17 1.41 -85 -53 -53 -28 -26 -30 -25 -26
Return On Investment Capital (ROIC_SIMPLE)		 - - 0.33% - - - -17.27% -13.14% -17.87% -7.60% -8.39%
Earnings before Interest and Taxes (EBIT)		 20 18 2.11 -123 -77 -76 -40 -38 -43 -36 -36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 18 16 -0.17 -125 -80 -78 -42 -40 -45 -37 -37
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -24 -64 -67 -30 24 49 45 -73 -66 -51 -23
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 29 63 62 -49 -49 -38 -12 -2.65 -13 -12 -14
Increase / (Decrease) in Invested Capital		 43 82 68 -56 -78 -102 -74 46 36 26 -2.46
Book Value per Share		 $5.75 $6.21 $6.42 $4.78 $3.84 $2.88 $2.40 $2.27 $1.88 $3.72 $2.78
Tangible Book Value per Share		 $5.75 $6.21 $6.42 $4.78 $3.84 $2.88 $2.40 $2.27 $1.88 $3.72 $2.78
Total Capital		 386 418 433 324 261 196 165 201 168 332 305
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -357 -355 -371 -373 -310 -234 -177 -204 -181 -344 -317
Capital Expenditures (CapEx)		 0.28 0.36 0.36 0.07 0.09 -0.02 0.02 0.01 0.02 0.02 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 6.04 33 11 -54 -53 -43 -15 -5.86 -15 -16 -16
Debt-free Net Working Capital (DFNWC)		 363 388 383 319 257 191 161 198 165 328 301
Net Working Capital (NWC)		 363 388 383 319 257 191 161 198 165 328 301
Net Nonoperating Expense (NNE)		 -3.50 -3.44 -3.32 33 19 20 9.09 9.44 11 9.17 7.38
Net Nonoperating Obligations (NNO)		 -357 -355 -371 -373 -310 -234 -177 -204 -181 -344 -319
Total Depreciation and Amortization (D&A)		 -1.70 -2.18 -2.27 -2.27 -2.97 -2.08 -1.63 -1.55 -1.38 -1.12 -0.95
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.33 $0.31 $0.07 ($1.75) ($1.07) ($1.07) ($0.54) ($0.42) ($0.46) ($0.37) ($0.28)
Adjusted Weighted Average Basic Shares Outstanding		 67.23M 67.41M 67.23M 67.85M 68.02M 68.09M 68.14M 85.70M 89.14M 93.33M 94.57M
Adjusted Diluted Earnings per Share		 $0.31 $0.30 $0.07 ($1.75) ($1.07) ($1.07) ($0.54) ($0.42) ($0.46) ($0.37) ($0.28)
Adjusted Weighted Average Diluted Shares Outstanding		 70.13M 69.75M 69.99M 67.85M 68.02M 68.09M 68.14M 85.70M 89.14M 93.33M 94.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 67.38M 67.52M 67.78M 68.01M 68.08M 68.55M 88.60M 89.14M 89.17M 109.82M 110.54M
Normalized Net Operating Profit after Tax (NOPAT)		 19 17 1.41 -85 -37 -53 -28 -26 -30 -25 -26
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Below is a concise, investor-focused summary of Amylyx Pharmaceuticals (AMLX) using the latest quarterly data you provided, focusing on liquidity, financing activity, and profitability trends over the last four years.

  • Significant cash inflows from the sale/maturity of investments across multiple quarters, notably about $60M in Q4 2025, $64M in Q3 2025, and roughly $65M in Q4 2024 (with a ~ $74M item in Q3 2024), which bolster AMLX’s liquidity runway.
  • In Q3 2025, AMLX issued debt that added roughly $191M of cash, providing a meaningful near-term liquidity cushion.
  • Equity financing in 2025 helped strengthen the balance sheet, with Q2 2025 common stock issuance lifting Total Common Equity to approximately $851M.
  • Net financing activities in Q3 2025 delivered a substantial cash inflow (about $191.6M) from continuing financing activities, supporting liquidity.
  • Cash on hand climbed to around $225M by Q3 2025, signaling improved liquidity, though cash generation from operations remains negative.
  • In Q2 2025, AMLX reported a liquidity mix of about $58M in cash and $123M in short-term investments (roughly $181M total), indicating a sizable liquidity cushion.
  • Operating revenue remains effectively zero across many quarters, underscoring that AMLX remains in a pre-revenue phase and relies on external funding for cash needs.
  • Persistent net losses in 2025: Q4 net income about -$33.0M; Q3 about -$34.4M; Q2 about -$41.4M; Q1 about -$35.9M, reflecting ongoing profitability challenges.
  • Operating cash flow from continuing operations was negative in 2025 (roughly -$25M to -$30M per quarter), indicating continued cash burn from operations.
  • High and rising research and development (R&D) and SG&A costs relative to near-term revenue contribute to ongoing losses (e.g., Q4 2025 SGA = $15.39M, RD = $21.21M; Total Operating Expenses = $36.60M).
05/05/26 02:07 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Amylyx Pharmaceuticals' Financials

When does Amylyx Pharmaceuticals' fiscal year end?

According to the most recent income statement we have on file, Amylyx Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Amylyx Pharmaceuticals' net income changed over the last 4 years?

Amylyx Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$144.74 million in 2025, rising from -$87.93 million in 2021. The previous period was -$301.74 million in 2024. View Amylyx Pharmaceuticals' forecast to see where analysts expect Amylyx Pharmaceuticals to go next.

What is Amylyx Pharmaceuticals' operating income?
Amylyx Pharmaceuticals' total operating income in 2025 was -$153.29 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $153.29 million
How has Amylyx Pharmaceuticals' revenue changed over the last 4 years?

Over the last 4 years, Amylyx Pharmaceuticals' total revenue changed from $285 thousand in 2021 to $0.00 in 2025, a change of -100.0%.

How much debt does Amylyx Pharmaceuticals have?

Amylyx Pharmaceuticals' total liabilities were at $27.39 million at the end of 2025, a 5.1% decrease from 2024, and a 57.1% increase since 2021.

How much cash does Amylyx Pharmaceuticals have?

In the past 4 years, Amylyx Pharmaceuticals' cash and equivalents has ranged from $50.19 million in 2021 to $226.65 million in 2025, and is currently $226.65 million as of their latest financial filing in 2025.

How has Amylyx Pharmaceuticals' book value per share changed over the last 4 years?

Over the last 4 years, Amylyx Pharmaceuticals' book value per share changed from -22.95 in 2021 to 2.78 in 2025, a change of -112.1%.


Related Companies

Financial statements for NASDAQ:AMLX last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel